Results 11 to 20 of about 2,337 (177)

SPP1 May Play an Important Role in the Carcinoid Nature of PAH. [PDF]

open access: yesMediators Inflamm
Objection Pulmonary arterial hypertension (PAH) was a cancer‐like disease. It shared several mechanisms, including perivascular inflammation. But the genes common and different between cancer and PAH was still unclear. We aimed to analyze the genes common in the two diseases, especially the N7‐methylguanosine (m7G) genes.
Huang Y, Yan S, Zhu J, Zhang W.
europepmc   +2 more sources

The CAR‐HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL

open access: yesAmerican Journal of Hematology, Volume 98, Issue 11, Page 1699-1710, November 2023., 2023
The CAR‐HEMATOTOX risk‐stratifies for toxicity and survival in relapsed/refractory MCL. Abstract CD19‐directed CAR T‐cell therapy with brexucabtagene autoleucel (brexu‐cel) has substantially improved treatment outcomes for patients with relapsed/refractory mantle cell lymphoma (r/r MCL).
Kai Rejeski   +19 more
wiley   +1 more source

The spliceosomal phosphopeptide P140 controls the lupus disease by interacting with the HSC70 protein and via a mechanism mediated by gammadelta T cells. [PDF]

open access: yesPLoS ONE, 2009
The phosphopeptide P140 issued from the spliceosomal U1-70K snRNP protein is recognized by lupus CD4(+) T cells, transiently abolishes T cell reactivity to other spliceosomal peptides in P140-treated MRL/lpr mice, and ameliorates their clinical features.
Nicolas Page   +9 more
doaj   +1 more source

Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR‐T for Relapsed/Refractory Large B‐cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR‐T Product Use

open access: yesHemaSphere, Volume 7, Issue 8, August 2023., 2023
Real‐world evidence suggests a trend toward inferior survival of patients receiving CD19 chimeric antigen receptor (CAR) T‐cell therapy in Europe (EU) and with tisagenlecleucel. The underlying logistic, patient‐ and disease‐related reasons for these discrepancies remain poorly understood.
Veit Bücklein   +26 more
wiley   +1 more source

Performance of a PLK1‐based immune risk model for prognosis and treatment response prediction in breast cancer

open access: yesCancer Medicine, Volume 12, Issue 9, Page 11020-11039, May 2023., 2023
PLK1 regulated the degree of immune cell (e.g., CD8+ T cells, Tregs, etc.) infiltration and immunomodulator expressions, thus participating in the tumor‐specific immune response. The PLK1‐based immune risk model could accurately identify immunotherapy‐or chemotherapy‐sensitive breast cancer patients, which is expected to act as a biomarker for ...
Yan Chen   +6 more
wiley   +1 more source

Potential use of [gammadelta] T cell-based vaccines in cancer immunotherapy

open access: yesFrontiers in Immunology, 2014
Immunotherapy is a fast advancing methodology involving one of two approaches: 1) compounds targeting immune checkpoints, and 2) cellular immunomodulators.
Mohd Wajid A. Khan   +2 more
doaj   +1 more source

Surfing on the waves of the human γδ T cell ontogenic sea

open access: yesImmunological Reviews, Volume 315, Issue 1, Page 89-107, May 2023., 2023
Summary While γδ T cells are present virtually in all vertebrates, there is a remarkable lack of conservation of the TRG and TRD loci underlying the generation of the γδ T cell receptor (TCR), which is associated with the generation of species‐specific γδ T cells.
Guillem Sanchez Sanchez   +3 more
wiley   +1 more source

Immune Profile of the Normal Maternal-Fetal Interface in Rhesus Macaques and Its Alteration Following Zika Virus Infection

open access: yesFrontiers in Immunology, 2021
The maternal decidua is an immunologically complex environment that balances maintenance of immune tolerance to fetal paternal antigens with protection of the fetus against vertical transmission of maternal pathogens.
Matilda J. Moström   +12 more
doaj   +1 more source

Gammadelta T cell modulation in anticancer treatment.

open access: yesCurrent cancer drug targets, 2010
The broad antimicrobial and antitumoral reactivity of Vgamma9Vdelta2 T cells, their ability to produce inflammatory cytokines involved in protective immunity against intracellular pathogens and tumors and their strong cytolytic and bactericidal activities suggest their direct involvement in immune control of cancers and infections.
CACCAMO, Nadia Rosalia   +4 more
openaire   +3 more sources

HAUS Augmin‐Like Complex Subunit 1 Influences Tumour Microenvironment and Prognostic Outcomes in Glioma

open access: yesJournal of Oncology, Volume 2022, Issue 1, 2022., 2022
Background. The expression of HAUS Augmin‐like complex subunit 1 (HAUS1), a protein‐coding gene, is low in normal samples among various cancers with pan‐cancer analysis. The depletion of HAUS1 in cells decreases the G2/M cell compartment and induces apoptosis.
Qi Yao   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy